Veeda Lifesciences Partners with Mango Sciences for AI-Driven Clinical Trials
Veeda Lifesciences has announced a partnership with Mango Sciences to integrate AI technology into its clinical trial services, announced in a press release. This collaboration aims to improve the speed, efficiency, and quality of clinical trials by leveraging Mango Sciences' AI-powered Querent™ platform.
The partnership will enable Veeda to automate patient identification and expand its reach across Europe, focusing on enhancing diversity in clinical trials. By utilizing advanced data analytics, the AI-driven platform will streamline processes, improve data management, and ensure higher quality standards through broader representation of non-Caucasian populations.
Dr. Mahesh Bhalgat, Group CEO and Managing Director of Veeda Clinical Research Limited, highlighted that this partnership will transform Veeda into an AI-driven oncology drug development organization. The integration of Large Language Models (LLMs) and Generative-AI into the Querent™ platform is expected to drive operational efficiencies and improve real-world evidence, ultimately identifying the right drug for the right patient.
Veeda's strategic investments, including the acquisition of Health Data Specialists, have strengthened its position as a tech-enabled, AI-driven CRO, providing access to oncology cohorts in India and Europe. This supports Veeda's aim to maintain a competitive edge in the CRO sector while delivering services to pharmaceutical and biopharmaceutical clients globally.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 30 Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354 Sep 29 Truven launches MarketScan Snapshot for healthcare data checks Sep 29 Omega Healthcare Wins Gold in 2026 AI Breakthrough Awards Sep 29 Phylo Launches Target Atlas for Drug Target Prioritization Sep 29 ChromAgeNet Detects Aging Signs in Blood Stem Cell ImagesLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Enveda Raises $311 Million for AI Drug Discovery
Veeva Introduces AI Agent for Clinical Study Configuration
Linearis Joins Two Canadian AI Health Data Projects
MediSights Reports Study Using AI Agents for Myeloma Market Research
Onymos and Vanta Diagnostics Report AI Lab Intake Results
Daily AI Brief: the AI news that matters, in your inbox.